The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Genentech; Gilead Sciences; Immunomedics; Novartis; Pfizer
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech/Roche; Gilead Sciences; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Macrogenics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus
Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
 
Xin Gao
Consulting or Advisory Role - Bayer; Dendreon; Exelixis; Flare Therapeutics; Guardant Health
Research Funding - Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Merck (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); BioTheryX (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CicloMed (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Vincerx Pharma (Inst)
 
Jacqueline Vuky
Consulting or Advisory Role - Seattle Genetics/Astellas
Research Funding - Arvinas (Inst); Celldex (Inst); Fortis (Inst); Innocrin Pharma (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Bayer; bristol -Myers Squibb; EMD Serono; Exelixis; Hinova Pharmaceuticals; Infinity Pharmaceuticals; Janssen Oncology; Merck; Myovant Sciences; Myovant Sciences; Pfizer; Propella Therapeutics; Seagen; Veru; Veru
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Seagen (Inst)
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics; PSMA Therapeutics; United Health Group
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Sanofi; Telix Pharmaceuticals; TeneoBio; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Foundation Medicine; Genzyme; Immunomedics; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday
 
Ivor John Percent
No Relationships to Disclose
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; Genentech; Merck; MLI PeerView; OncLive; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Research to Practice; Sanofi; UroToday; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Daiichi Sankyo Company; Genentech; Janssen; Merck; Novartis; Pfizer; Pfizer
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer
 
Arash Rezazadeh Kalebasty
No Relationships to Disclose
 
John Shen
Consulting or Advisory Role - AstraZeneca
Research Funding - Ambrx (Inst); Arvinas (Inst); Bayer (Inst); BMS (Inst); Macrogenics (Inst); Merck (Inst)
 
Elisabeth I. Heath
Honoraria - AstraZeneca; Bayer; Dendreon; Sanofi; Seagen
Consulting or Advisory Role - Agensys; AstraZeneca; Bayer; Dendreon; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Agensys; Bayer; Sanofi
Other Relationship - Caris Centers of Excellence
 
Guillermo Abesada-Terk
No Relationships to Disclose
 
Sunil G. Gandhi
No Relationships to Disclose
 
Meredith McKean
Consulting or Advisory Role - Array BioPharma (Inst); AstraZeneca (Inst); Pfizer (Inst); Regeneron (Inst)
Research Funding - Ascentage Pharma Group (Inst); Bicycle Therapeutics (Inst); Dragonfly Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Novartis (Inst); Oncorus (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst)
 
Haolan Lu
Employment - 3D Medicines; Arvinas
Stock and Other Ownership Interests - Arvinas
Travel, Accommodations, Expenses - 3D Medicines; Arvinas
 
Elmer Berghorn
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas
 
Richard Gedrich
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas
 
S. Debbie Chirnomas
Employment - Arvinas
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Merck; Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; on quality; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi